{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,9]],"date-time":"2026-04-09T00:48:35Z","timestamp":1775695715590,"version":"3.50.1"},"reference-count":35,"publisher":"Springer Science and Business Media LLC","issue":"6","license":[{"start":{"date-parts":[[2025,10,30]],"date-time":"2025-10-30T00:00:00Z","timestamp":1761782400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2025,10,30]],"date-time":"2025-10-30T00:00:00Z","timestamp":1761782400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"funder":[{"DOI":"10.13039\/100006396","name":"Alexion Pharmaceuticals","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100006396","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Neurol Ther"],"published-print":{"date-parts":[[2025,12]]},"DOI":"10.1007\/s40120-025-00846-3","type":"journal-article","created":{"date-parts":[[2025,10,30]],"date-time":"2025-10-30T18:15:55Z","timestamp":1761848155000},"page":"2723-2736","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Switching from Rituximab to Eculizumab in US Patients with Neuromyelitis Optica Spectrum Disorder: Impact on Hospitalizations"],"prefix":"10.1007","volume":"14","author":[{"ORCID":"https:\/\/orcid.org\/0009-0004-9689-5300","authenticated-orcid":false,"given":"Justin","family":"Lee","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0009-0006-4975-2045","authenticated-orcid":false,"given":"Adrian","family":"Kielhorn","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sami","family":"Fam","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Emily","family":"Riser","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6661-2910","authenticated-orcid":false,"given":"Eoin P.","family":"Flanagan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2025,10,30]]},"reference":[{"issue":"7","key":"846_CR1","doi-asserted-by":"publisher","first-page":"631","DOI":"10.1056\/NEJMra1904655","volume":"387","author":"DM Wingerchuk","year":"2022","unstructured":"Wingerchuk DM, Lucchinetti CF. Neuromyelitis optica spectrum disorder. N Engl J Med. 2022;387(7):631\u20139.","journal-title":"N Engl J Med"},{"issue":"9","key":"846_CR2","doi-asserted-by":"publisher","first-page":"805","DOI":"10.1016\/S1474-4422(07)70216-8","volume":"6","author":"DM Wingerchuk","year":"2007","unstructured":"Wingerchuk DM, Lennon VA, Lucchinetti CF, Pittock SJ, Weinshenker BG. The spectrum of neuromyelitis optica. Lancet Neurol. 2007;6(9):805\u201315.","journal-title":"Lancet Neurol"},{"issue":"1","key":"846_CR3","doi-asserted-by":"publisher","first-page":"141","DOI":"10.1007\/s00415-023-11910-z","volume":"271","author":"T Kumpfel","year":"2024","unstructured":"Kumpfel T, Giglhuber K, Aktas O, et al. Update on the diagnosis and treatment of neuromyelitis optica spectrum disorders (NMOSD)\u2014revised recommendations of the Neuromyelitis Optica Study Group (NEMOS). Part II: attack therapy and long-term management. J Neurol. 2024;271(1):141\u201376.","journal-title":"J Neurol"},{"issue":"2","key":"846_CR4","doi-asserted-by":"publisher","first-page":"177","DOI":"10.1212\/WNL.0000000000001729","volume":"85","author":"DM Wingerchuk","year":"2015","unstructured":"Wingerchuk DM, Banwell B, Bennett JL, et al. International consensus diagnostic criteria for neuromyelitis optica spectrum disorders. Neurology. 2015;85(2):177\u201389.","journal-title":"Neurology"},{"issue":"1","key":"846_CR5","doi-asserted-by":"publisher","DOI":"10.1038\/s41572-020-0214-9","volume":"6","author":"S Jarius","year":"2020","unstructured":"Jarius S, Paul F, Weinshenker BG, Levy M, Kim HJ, Wildemann B. Neuromyelitis optica. Nat Rev Dis Primers. 2020;6(1):85.","journal-title":"Nat Rev Dis Primers"},{"issue":"7","key":"846_CR6","doi-asserted-by":"publisher","first-page":"981","DOI":"10.1111\/cns.13836","volume":"28","author":"M Shi","year":"2022","unstructured":"Shi M, Chu F, Jin T, Zhu J. Progress in treatment of neuromyelitis optica spectrum disorders (NMOSD): novel insights into therapeutic possibilities in NMOSD. CNS Neurosci Ther. 2022;28(7):981\u201391.","journal-title":"CNS Neurosci Ther"},{"key":"846_CR7","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.86.16_supplement.P6.161","volume":"86","author":"D Stafkey-Mailey","year":"2016","unstructured":"Stafkey-Mailey D, Boscoe A, Ajmera M, Mauskopf J, Iloeje U, Levy M. A real-world analysis of relapses and costs of neuromyelitis optica spectrum disorders using a United States administrative claims database. Neurology. 2016;86:6.161.","journal-title":"Neurology"},{"issue":"2","key":"846_CR8","doi-asserted-by":"publisher","first-page":"767","DOI":"10.1007\/s40120-021-00253-4","volume":"10","author":"M Royston","year":"2021","unstructured":"Royston M, Kielhorn A, Weycker D, et al. Neuromyelitis optica spectrum disorder: clinical burden and cost of relapses and disease-related care in US clinical practice. Neurol Ther. 2021;10(2):767\u201383.","journal-title":"Neurol Ther"},{"issue":"1","key":"846_CR9","doi-asserted-by":"publisher","first-page":"247","DOI":"10.1007\/s40120-021-00311-x","volume":"11","author":"RK Knapp","year":"2022","unstructured":"Knapp RK, Hardtstock F, Wilke T, et al. Evaluating the economic burden of relapses in neuromyelitis optica spectrum disorder: a real-world analysis using German claims data. Neurol Ther. 2022;11(1):247\u201363.","journal-title":"Neurol Ther"},{"issue":"1","key":"846_CR10","doi-asserted-by":"publisher","first-page":"159","DOI":"10.1186\/s13023-022-02310-z","volume":"17","author":"DA Hughes","year":"2022","unstructured":"Hughes DA, Bourke S, Jones A, et al. Health utilities and costs for neuromyelitis optica spectrum disorder. Orphanet J Rare Dis. 2022;17(1):159.","journal-title":"Orphanet J Rare Dis"},{"key":"846_CR11","unstructured":"Soliris (eculizumab) [prescribing information]. Boston, MA: Alexion Pharmaceuticals, Inc; 2025."},{"key":"846_CR12","unstructured":"Uplizna (inebilizumab) [prescribing information]. Deerfield, IL: Horizon Therapeutics, Inc; 2025."},{"key":"846_CR13","unstructured":"Ensprying (satralizumab) [prescribing information]. South San Francisco, CA: Genentech, Inc; 2022."},{"key":"846_CR14","unstructured":"Ultomiris (ravulizumab-cwvz) [prescribing information]. Boston, MA: Alexion Pharmaceuticals; 2024."},{"key":"846_CR15","doi-asserted-by":"publisher","DOI":"10.1016\/j.bpg.2021.101757","volume":"54\u201355","author":"M Meneghini","year":"2021","unstructured":"Meneghini M, Bestard O, Grinyo JM. Immunosuppressive drugs modes of action. Best Pract Res Clin Gastroenterol. 2021;54\u201355:101757.","journal-title":"Best Pract Res Clin Gastroenterol"},{"issue":"3","key":"846_CR16","doi-asserted-by":"publisher","first-page":"229","DOI":"10.4103\/aian.AIAN_499_16","volume":"20","author":"JD Jade","year":"2017","unstructured":"Jade JD, Bansi S, Singhal B. Rituximab in neuromyelitis optica spectrum disorders: our experience. Ann Indian Acad Neurol. 2017;20(3):229\u201332.","journal-title":"Ann Indian Acad Neurol"},{"issue":"1","key":"846_CR17","doi-asserted-by":"publisher","first-page":"3503","DOI":"10.1038\/s41598-024-53838-y","volume":"14","author":"T Ongphichetmetha","year":"2024","unstructured":"Ongphichetmetha T, Jitprapaikulsan J, Siritho S, Rattanathamsakul N, Detweeratham T, Prayoonwiwat N. Efficacy and safety of rituximab in multiple sclerosis and neuromyelitis optica spectrum disorder. Sci Rep. 2024;14(1):3503.","journal-title":"Sci Rep"},{"issue":"4","key":"846_CR18","doi-asserted-by":"publisher","first-page":"298","DOI":"10.1016\/S1474-4422(20)30066-1","volume":"19","author":"M Tahara","year":"2020","unstructured":"Tahara M, Oeda T, Okada K, et al. Safety and efficacy of rituximab in neuromyelitis optica spectrum disorders (RIN-1 study): a multicentre, randomised, double-blind, placebo-controlled trial. Lancet Neurol. 2020;19(4):298\u2013306.","journal-title":"Lancet Neurol"},{"issue":"8","key":"846_CR19","doi-asserted-by":"publisher","first-page":"639","DOI":"10.1136\/jnnp-2017-315603","volume":"88","author":"JP Stellmann","year":"2017","unstructured":"Stellmann JP, Krumbholz M, Friede T, et al. Immunotherapies in neuromyelitis optica spectrum disorder: efficacy and predictors of response. J Neurol Neurosurg Psychiatry. 2017;88(8):639\u201347.","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"846_CR20","doi-asserted-by":"publisher","DOI":"10.1136\/jnnp-2024-334764","author":"V H\u00e4u\u00dfler","year":"2024","unstructured":"H\u00e4u\u00dfler V, Trebst C, Engels D, et al. Real-world multicentre cohort study on choices and effectiveness of immunotherapies in NMOSD and MOGAD. J Neurol Neurosurg Psychiatry. 2024. https:\/\/doi.org\/10.1136\/jnnp-2024-334764.","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"846_CR21","doi-asserted-by":"publisher","DOI":"10.1016\/j.msard.2021.102869","volume":"50","author":"M Velasco","year":"2021","unstructured":"Velasco M, Zarco LA, Agudelo-Arrieta M, Torres-Camacho I, Garcia-Cifuentes E, Mu\u00f1oz O. Effectiveness of treatments in neuromyelitis optica to modify the course of disease in adult patients. Systematic review of literature. Mult Scler Relat Disord. 2021;50:102869.","journal-title":"Mult Scler Relat Disord"},{"issue":"5","key":"846_CR22","doi-asserted-by":"publisher","DOI":"10.1212\/NXI.0000000000001179","volume":"9","author":"SH Kim","year":"2022","unstructured":"Kim SH, Park NY, Kim KH, Hyun JW, Kim HJ. Rituximab-induced hypogammaglobulinemia and risk of infection in neuromyelitis optica spectrum disorders: a 14-year real-life experience. Neurol Neuroimmunol Neuroinflamm. 2022;9(5):e1179.","journal-title":"Neurol Neuroimmunol Neuroinflamm"},{"key":"846_CR23","doi-asserted-by":"crossref","unstructured":"Bilodeau P-A, Narasimhan S, Pua DK, et al. Comparative effectiveness and safety of disease-modifying treatments (DMTs) in a real-world neuromyelitis optica spectrum disorder cohort (NMOSD). Presented at ECTRIMS annual congress; September 18\u201320, 2024; Copenhagen, Denmark.","DOI":"10.1212\/01.wnl.0001051756.04772.40"},{"issue":"3","key":"846_CR24","doi-asserted-by":"publisher","DOI":"10.1212\/NXI.0000000000000977","volume":"8","author":"A Avouac","year":"2021","unstructured":"Avouac A, Maarouf A, Stellmann JP, et al. Rituximab-induced hypogammaglobulinemia and infections in AQP4 and MOG antibody-associated diseases. Neurol Neuroimmunol Neuroinflamm. 2021;8(3):e977.","journal-title":"Neurol Neuroimmunol Neuroinflamm"},{"issue":"22","key":"846_CR25","doi-asserted-by":"publisher","first-page":"e2504","DOI":"10.1212\/WNL.0000000000201260","volume":"99","author":"P Barreras","year":"2022","unstructured":"Barreras P, Vasileiou ES, Filippatou AG, et al. Long-term effectiveness and safety of rituximab in neuromyelitis optica spectrum disorder and MOG antibody disease. Neurology. 2022;99(22):e2504\u201316.","journal-title":"Neurology"},{"issue":"6","key":"846_CR26","doi-asserted-by":"publisher","first-page":"1088","DOI":"10.1002\/ana.26049","volume":"89","author":"DM Wingerchuk","year":"2021","unstructured":"Wingerchuk DM, Fujihara K, Palace J, et al. Long-term safety and efficacy of eculizumab in aquaporin-4 IgG-positive NMOSD. Ann Neurol. 2021;89(6):1088\u201398.","journal-title":"Ann Neurol"},{"issue":"7","key":"846_CR27","doi-asserted-by":"publisher","first-page":"614","DOI":"10.1056\/NEJMoa1900866","volume":"381","author":"SJ Pittock","year":"2019","unstructured":"Pittock SJ, Berthele A, Fujihara K, et al. Eculizumab in aquaporin-4-positive neuromyelitis optica spectrum disorder. N Engl J Med. 2019;381(7):614\u201325.","journal-title":"N Engl J Med"},{"issue":"6","key":"846_CR28","doi-asserted-by":"publisher","first-page":"1053","DOI":"10.1002\/ana.26626","volume":"93","author":"SJ Pittock","year":"2023","unstructured":"Pittock SJ, Barnett M, Bennett JL, et al. Ravulizumab in aquaporin-4-positive neuromyelitis optica spectrum disorder. Ann Neurol. 2023;93(6):1053\u201368.","journal-title":"Ann Neurol"},{"key":"846_CR29","doi-asserted-by":"publisher","first-page":"175628642311811","DOI":"10.1177\/17562864231181177","volume":"16","author":"I Nakashima","year":"2023","unstructured":"Nakashima I, Nakahara J, Yokote H, et al. Long-term safety and effectiveness of eculizumab in patients with aquaporin-4 antibody-positive neuromyelitis optica spectrum disorder: a 2-year interim analysis of post-marketing surveillance in Japan. Ther Adv Neurol Disord. 2023;16:17562864231181176.","journal-title":"Ther Adv Neurol Disord"},{"key":"846_CR30","unstructured":"Fam S, Parks B, Allen K, et al. Meningococcal infections in eculizumab- or ravulizumab-treated patients: a clinical and real-world pharmacovigilance update across indications, including neuromyelitis optica spectrum disorder. Presented at ECTRIMS annual congress; September 18\u201320, 2024; Copenhagen, Denmark."},{"key":"846_CR31","doi-asserted-by":"publisher","DOI":"10.1016\/j.msard.2020.102641","volume":"47","author":"J Palace","year":"2021","unstructured":"Palace J, Wingerchuk DM, Fujihara K, et al. Benefits of eculizumab in AQP4+ neuromyelitis optica spectrum disorder: subgroup analyses of the randomized controlled phase\u00a03 PREVENT trial. Mult Scler Relat Disord. 2021;47:102641.","journal-title":"Mult Scler Relat Disord"},{"key":"846_CR32","unstructured":"IQVIA PharMetrics\u00ae Plus Fact Sheet. https:\/\/www.iqvia.com\/locations\/united-states\/library\/fact-sheets\/iqvia-pharmetrics-plus. Accessed 2 Sept 2025."},{"issue":"11","key":"846_CR33","doi-asserted-by":"publisher","first-page":"2010","DOI":"10.1377\/hlthaff.2020.00980","volume":"39","author":"JD Birkmeyer","year":"2020","unstructured":"Birkmeyer JD, Barnato A, Birkmeyer N, Bessler R, Skinner J. The impact of the COVID-19 pandemic on hospital admissions in the United States. Health Aff (Millwood). 2020;39(11):2010\u20137.","journal-title":"Health Aff (Millwood)"},{"key":"846_CR34","unstructured":"FDA approves first treatment for neuromyelitis optica spectrum disorder, a rare autoimmune disease of the central nervous system [press release]. https:\/\/wayback.archive-it.org\/7993\/20201229023444\/https:\/\/www.fda.gov\/news-events\/press-announcements\/fda-approves-first-treatment-neuromyelitis-optica-spectrum-disorder-rare-autoimmune-disease-central. Accessed 2 Sept 2025."},{"issue":"1","key":"846_CR35","doi-asserted-by":"publisher","first-page":"163","DOI":"10.1186\/s13023-022-02299-5","volume":"17","author":"G Yang","year":"2022","unstructured":"Yang G, Cintina I, Pariser A, Oehrlein E, Sullivan J, Kennedy A. The national economic burden of rare disease in the United States in 2019. Orphanet J Rare Dis. 2022;17(1):163.","journal-title":"Orphanet J Rare Dis"}],"container-title":["Neurology and Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40120-025-00846-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40120-025-00846-3\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40120-025-00846-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,11,17]],"date-time":"2025-11-17T10:45:10Z","timestamp":1763376310000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s40120-025-00846-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,10,30]]},"references-count":35,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2025,12]]}},"alternative-id":["846"],"URL":"https:\/\/doi.org\/10.1007\/s40120-025-00846-3","relation":{},"ISSN":["2193-8253","2193-6536"],"issn-type":[{"value":"2193-8253","type":"print"},{"value":"2193-6536","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,10,30]]},"assertion":[{"value":"13 June 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"13 October 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"30 October 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Justin Lee, Adrian Kielhorn, and Sami Fam are employees of Alexion, AstraZeneca Rare Disease, Boston, MA, USA. Emily Riser is employed by Alabama Neurology Associates, Birmingham, AL, USA and has received funding from Corvitas and Alexion, AstraZeneca Rare Disease for NMO Registries. Eoin P. Flanagan has served on advisory boards for Alexion, AstraZeneca Rare Disease, Genentech, Horizon Therapeutics, and UCB; has received research support from UCB, speaker honoraria from Pharmacy Times, and royalties from UpToDate; was a site primary investigator in a randomized clinical trial on inebilizumab in neuromyelitis optica spectrum disorder run by Medimmune\/Viela-Bio\/Horizon Therapeutics; has received funding from the NIH (R01NS113828); is a member of the medical advisory board of the MOG project; is an editorial board member of the\n                      Journal of the Neurological Sciences\n                      and\n                      Neuroimmunology Reports\n                      ; and has submitted a patent on DACH1-IgG as a biomarker of paraneoplastic autoimmunity. The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of Interest"}},{"value":"This study was conducted in accordance with the ethical principles of the Declaration of Helsinki and are consistent with Good Clinical Practice and applicable regulatory requirements. All data and subsequent analyses are compliant with the Health Insurance Portability and Accountability Act (HIPAA) to guard patients\u2019 privacy. The retrospective claims data were de-identified according to regulations. Federal guidance on Public Welfare and Protection of Human Subjects was followed. This study was determined to be exempt from an IRB and informed consent was not required.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical Approval"}}]}}